Skip to content

US · BCAB · BIOTECHNOLOGY

BioAtla, Inc. (BCAB) intrinsic value and stock valuation

$1.74as of 2026-11-21 · Mkt cap 4.19M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

BioAtla, Inc. DCF and intrinsic value

InvestorsCraft values BCAB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BCAB’s statements →

BioAtla, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92121 bioatla.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$2M+36% 5y CAGRd
20182025
Net income
-$-59.61M
20182025
Free cash flow
-$-48.2M
20182025
Total equity
-$-36.19M
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$2M$11M$0.00$0.00$250K
Operating income-$-59.3M-$-73.94M-$-129.69M-$-108.14M-$-96.44M
Net income-$-59.61M-$-69.78M-$-123.46M-$-105.28M-$-95.4M
EPSd-$-50.52M-$-71.94M-$-128.6M-$-134.97M-$-138.26M
Operating cash flow-$-48.2M-$-71.94M-$-104.02M-$-90.42M-$-62.21M
Capital expenditure$0.00$0.00-$-100K-$-270K-$-920K
Free cash flow-$-48.2M-$-71.94M-$-104.11M-$-90.69M-$-63.14M
Total assets$13.8M$52.4M$119.7M$225.7M$254.4M
Total debt$6.2M$840K$2.46M$3.98M$5.37M
Net debt-$-920K-$-48.21M-$-109.01M-$-211.53M-$-239.61M
Total equity-$-36.19M$14.3M$70.7M$180.3M$210.8M
Cash and short-term investments$7.12M$49.1M$111.5M$215.5M$245M
Income statement
20252024202320222021
Revenue$2M$11M$0.00$0.00$250K
Cost of revenue$43.1M$930K$1.22M$1.2M$58.3M
Gross profit-$-41.07M$10.1M-$-1.22M-$-1.2M-$-58.02M
Research and development expenses$43.6M$63.1M$103.7M$79.4M$58.3M
Selling, general and administrative expenses$17.6M$21.9M$26M$28.8M$38.4M
Other expenses-$-42.97M-$-930K-$-1.22M-$-1.2M-$-58.27M
Operating expenses$18.2M$84M$128.5M$106.9M$38.4M
Cost and expenses$61.3M$84.9M$129.7M$108.1M$96.7M
Interest income$840K$3.37M$6.31M$1.65M$350K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$370K$930K$1.22M$1.2M$1.33M
Ebitda-$-59.23M-$-68.85M-$-122.24M-$-105.28M-$-94.07M
Operating income-$-59.3M-$-73.94M-$-129.69M-$-108.14M-$-96.44M
Total other income/expenses, net-$-300K$4.17M$6.22M$1.66M$1.04M
Income before tax-$-59.61M-$-69.78M-$-123.46M-$-106.48M-$-95.4M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-59.61M-$-69.78M-$-123.46M-$-105.28M-$-95.4M
Weighted average shares outstanding$1.18M$970K$960K$780K$690K
Weighted average diluted shares outstanding$1.18M$970K$960K$780K$690K
Balance sheet
20252024202320222021
Cash and short-term investments$7.12M$49.1M$111.5M$215.5M$245M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$8.01M$51.2M$116.4M$220.4M$247.3M
Property, plant and equipment, net$5.65M$1.19M$3.1M$5.15M$6.98M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$5.82M$1.19M$3.25M$5.3M$7.13M
Total assets$13.8M$52.4M$119.7M$225.7M$254.4M
Accounts payable$8.19M$1.9M$3.82M$4.23M$1.18M
Short-term debt$1.43M$840K$1.62M$1.52M$1.39M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$21.9M$14.5M$28.3M$23.1M$19.8M
Long-term debt$4.77M$0.00$840K$2.46M$3.98M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$28.1M$23.6M$20.6M$22.3M$23.8M
Capital lease obligations$1.43M$840K$2.46M$3.98M$5.37M
Total liabilities$50M$38.2M$49M$45.4M$43.6M
Common stock$10K$10K$10K$10K$0.00
Retained earnings-$-545.65M-$-486.04M-$-416.26M-$-292.8M-$-186.32M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00-$0.00
Total equity-$-36.19M$14.3M$70.7M$180.3M$210.8M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$6.2M$840K$2.46M$3.98M$5.37M
Net debt-$-920K-$-48.21M-$-109.01M-$-211.53M-$-239.61M
Cash flow statement
20252024202320222021
Net income-$-59.61M-$-69.78M-$-123.46M-$-106.48M-$-95.4M
Depreciation and amortization$370K$930K$1.22M$1.2M$1.33M
Stock-based compensation$5.43M$8.92M$13.5M$14.6M$25.1M
Change in working capital$4.28M-$-11.2M$4.68M$290K$7.42M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$2.8M-$-13.46M$5.28M$3.41M$7.99M
Net cash provided by operating activities-$-48.2M-$-71.94M-$-104.02M-$-90.42M-$-62.21M
Investments in property, plant and equipment$0.00$0.00-$-100K-$-270K-$-920K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00-$-100K-$-270K-$-920K
Common stock issued$100K$9.21M$340K$61.7M$71M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$6.28M$9.51M$80K$61.2M$69.5M
Net change in cash-$-41.93M-$-62.42M-$-104.04M-$-29.47M$6.37M
Cash at end of period$7.12M$49.1M$111.5M$215.5M$245M
Operating cash flow-$-48.2M-$-71.94M-$-104.02M-$-90.42M-$-62.21M
Capital expenditure$0.00$0.00-$-100K-$-270K-$-920K
Free cash flow-$-48.2M-$-71.94M-$-104.11M-$-90.69M-$-63.14M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About BioAtla, Inc.

        BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.

        CEO
        Jay Short
        Employees
        41
        Beta
        0.75

        Explore

        Frequently asked questions

        What is the intrinsic value of BioAtla, Inc. (BCAB)?

        InvestorsCraft does not currently publish an intrinsic value for BCAB. How the IC value is calculated.

        Is BCAB undervalued?

        InvestorsCraft does not publish an undervaluation signal for BCAB at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.